Bayer launches Sativex in the UK
This article was originally published in Scrip
Executive Summary
Bayer Schering Pharma has launched GW Pharmaceuticals' cannabinoid spray product Sativex (nabiximols) as an add-on treatment of spasticity due to multiple sclerosis (MS) in the UK – the first country to grant the product a full approval.